TABLE 1.
Baseline characteristics.
| Tofacitinib (n = 110) | ||
|---|---|---|
| Age (years) | Mean (SD) | 45 (14) |
| Female | N (%) | 50 (45.5) |
| Disease duration (years) | Median (IQR) | 7 (3–14) |
| Follow‐up (weeks) | Mean (SD) | 102 (7) |
| BMI | Mean (SD) | 24.8 (4.2) |
| Disease activity | ||
| SCCAI‐score | Median (IQR) | 7 (5–10) |
| CRP (mg/L), n = 103 | Median (IQR) | 5.9 (2–13) |
| FC (mg/kg), n = 88 | Median (IQR) | 1765 (633–2763) |
| Medical history | ||
| Disease location a | ||
| Proctitis | N (%) | 8 (7.3) |
| Left‐sided | N (%) | 36 (32.7) |
| Pancolitis | N (%) | 64 (58.2) |
| Unknown | N (%) | 2 (1.8) |
| Prior treatment | ||
| Prior thiopurine | N (%) | 95 (86.4) |
| Prior ≥1 anti‐TNF | N (%) | 104 (94.5) |
| Prior ≥2 anti‐TNF | N (%) | 41 (37.2) |
| Prior vedolizumab | N (%) | 67 (60.9) |
| Prior ustekinumab | N (%) | 4 (3.6) |
| JAK inhibitor | ||
| Concomitant treatment | ||
| Oral prednisone | N (%) | 41 (37.3) |
| Oral prednisone dose | mg (IQR) | 20 (15–30) |
| Budesonide | N (%) | 17 (15.5) |
| Mesalazine | N (%) | 40 (36.4) |
| Thiopurine | N (%) | 3 (2.7) |
| Methotrexate | N (%) | 2 (1.8) |
Abbreviations: BMI, body mass index; CRP, C‐reactive protein; FC, faecal calprotectin; SCCAI, Simple Clinical Colitis Activity Index.
a
Maximum extend until inclusion.